15^th World Medical Nanotechnology Congress

Biography

Dr. Rupinder K Kanwar completed her PhD from PGIMER, India. Since then she has worked in India, New Zealand and Australia, in a variety of positions supporting and building new research programs related to interdisciplinary research, international collaborations and large-scale initiatives ranging from biomedicine to nanomedicine. She has 15 years’ experience in drug discovery targeting cancer and chronic inflammation, and delivered both academic and industry-oriented research with 75 peer reviewed publications. Dr Kanwar is a key inventor in more than 20 published and live patents/ applications. Her current research focuses on targeting molecular pathogenesis of chronic inflammatory diseases and cancer with nanodrug and nanodiagnostic developments. At Deakin University, she is providing leadership to her research team on deciphering novel molecular targets for protein biodrugs to treat cancer and cardiomyopathy. She serves as an editorial advisory board member and reviewer of several international journals. Dr Kanwar has been invited as a speaker, and chair in national & international conferences, and her research presentations won awards at conferences

Research Interest

Dr RK Kanwar has expertise in applying cutting edge techniques of immunology, cell biology, molecular biology to study the pathophysiology and therapeutic targets of human cancer and chronic inflammatory diseases (atherosclerosis, asthma and multiple sclerosis) in both in vivo and in vitro models. Dr Kanwar also has skills in delivering industry oriented research and is a key inventor on number of recent patent applications on devising treatments for chronic inflammatory diseases. Her current research focus is on combining nanomedicinal approaches with basic cell biology and immunology research, to devise diagnostics and therapeutics for cancer drug resistance, stemcells, and chronic inflammatory disease (atherosclerosis and osteoarthritis).